Plozasiran (Redemplo) — coverage criteria for familial chylomicronemia syndrome
Customize your policy alerts
Sign up for QualChoice Policy CP.PHAR.721 alerts
Get alerted when Policy CP.PHAR.721 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical necessity criteria, prior authorization, and coverage for plozasiran (Redemplo) as adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) for QualChoice lines of business.
Added option for prescription by gastroenterologist or pancreatologist.
In continued therapy, specified that Redemplo is not prescribed concurrently with Tryngolza.
Consolidated FCS diagnostic criteria and added requirement for history of triglycerides >1,000 mg/dL at least three times for clinically suggestive FCS.
Added ICHRA line of business.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.